New therapeutic target expands options for multiple myeloma
July 22, 2026
July 22, 2026
PHILADELPHIA, Pennsylvania, July 22 -- The University of Pennsylvania Perelman School of Medicine posted the following news:
* * *
New therapeutic target expands options for multiple myeloma
*
In a Phase I clinical trial, treatment with the investigational bispecific antibody cevostamab reduced cancer in more than 40 percent of patients with multiple myeloma, many of whom had already been through multiple other cancer treatments, and produced a . . .
* * *
New therapeutic target expands options for multiple myeloma
*
In a Phase I clinical trial, treatment with the investigational bispecific antibody cevostamab reduced cancer in more than 40 percent of patients with multiple myeloma, many of whom had already been through multiple other cancer treatments, and produced a . . .